Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders

P. Gunerka, O. Musielak, B. Dymek, D. Zdzalik, M. Zagozda, M. Dziachan, M. Malczyk, A. Bujak, P. Grygielewicz, M. Skupinska, J. Hucz-Kalitowska, K. Dubiel, M. Lamparska-Przybysz, M. Wierczorek, A. Stanczak (Lomianki, Warsaw, Lodz, Poland)

Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Session: New treatments for cough, asthma, COPD and ILDs
Session type: Poster Discussion
Number: 1505
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Gunerka, O. Musielak, B. Dymek, D. Zdzalik, M. Zagozda, M. Dziachan, M. Malczyk, A. Bujak, P. Grygielewicz, M. Skupinska, J. Hucz-Kalitowska, K. Dubiel, M. Lamparska-Przybysz, M. Wierczorek, A. Stanczak (Lomianki, Warsaw, Lodz, Poland). Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders. Eur Respir J 2014; 44: Suppl. 58, 1505

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013


In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014


Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015

In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014


RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

In vitro profile of the new inhaled pan-JAK inhibitor LAS194046
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351)
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013

The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014

In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014


Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014

AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016